Chinese english Japanese Germany Korea
ChemicalBook > Product Catalog >Organic Chemistry >Amides >Sulfonic acids amino compound >Lapatinib ditosylate

Lapatinib ditosylate

Lapatinib ditosylate Structure
CAS No.
388082-78-8
Chemical Name:
Lapatinib ditosylate
Synonyms
Lapatinib ditosylate Monohydrate;Lapatinib tosilate;Lapatinib ditosylate hydrate;Lapatinb;GW2016 ditosylate;GW-572016;GW572016;(E)-Ferulic acid-d;lapatinib(GW572016);Lapatinib Ditosilate;Lapatinib ditosylate
CBNumber:
CB2966227
Molecular Formula:
C41H40ClFN4O11S3
Molecular Weight:
925.46
MOL File:
388082-78-8.mol
MSDS File:
SDS
Modify Date:
2024/6/19 22:55:17
Request For Quotation

Lapatinib ditosylate Properties

Melting point >200oC (dec.)
storage temp. under inert gas (nitrogen or Argon) at 2-8°C
solubility DMSO (Slightly), Methanol (Slightly)
form Solid
color Yellow
CAS DataBase Reference 388082-78-8(CAS DataBase Reference)

SAFETY

Risk and Safety Statements

Hazard statements  H413

Lapatinib ditosylate Chemical Properties,Uses,Production

Uses

Lapatinib ditosylate monohydrate is a form of Lapatinib I, an orally active drug for breast cancer as a dual EGFR and erbB-?2 inhibitor.

General Description

Lapatinib is available in 250-mg tablets for oral administrationand is used in combination with cabecitabine in thetreatment of breast cancer for those patients that over expressthe type 2 EGF-R and who have previously receivedtaxane, anthracycline, and trastuzumab therapy. The type 2EGF-R is one subtype of this receptor and is also known asHER2 or ErbB-2. The agent is a receptor TK inhibitor targetingthe ErbB-1 and ErbB-2 subtypes. Binding occurs atthe ATP-binding site and thereby prevents phosphorylationand the subsequent activation of other kinase enzymes.ErbB-1 overexpression occurs in approximately27% to 30% of breast cancers, while ErbB-2 is over expressedin 20% to 25% of cases.The agent has demonstratedIC50 values of ＜0.2μM against ErbB-1 and 2 fromseveral different cancer cell lines and dissociates slowly(t1/2＝300 min) from these receptor TKs.The drug isboth a substrate and an inhibitor of the efflux transportersPgp and BCRP. It is also an inhibitor of the hepatic uptaketransporter OATP1B1, which is an organic anion transporter.The absorption of lapatinib is incomplete andvariable after oral administration. The agent is extensivelymetabolized by CYP3A4 and CYP3A5, with minor contributionsfrom CYP2C19 and CYP2C8. Lapatinib inhibitsCYP3A and CYP2C8 at clinically relevant concentrations.The agent is highly (99%) protein bound and eliminatedprimarily in the feces. The half-life of the agent increaseupon repeated dosing, taking 6 days to reach steady statethat gives an effective half-life of 24 hours. The most commonlyseen adverse effects of lapatinib therapy are skinrash and diarrhea. Skin rash is commonly seen with manyof the other TK inhibitors and agents that target ErbB-1.Lapatinib-induced diarrhea is usually mild to moderate.There have been reports of decreases in left ventricularejection fraction associated with the agent, although thisappears to occur only rarely and is reversible upon discontinuationof therapy.

Lapatinib ditosylate Preparation Products And Raw materials

Raw materials

5-[4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl]-2-furaldehyde 2-Aminoethylmethylsulfone hydrochloride 2-Aminoethylmethyl sulfone p-Toluenesulfonic acid

Preparation Products

Lapatinib

Lapatinib ditosylate Suppliers

Global( 351)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
Salvavidas Pharmaceutical Pvt., Ltd. +91-2612538898 +91-9327127459 Gujarat, India 34 58 Inquiry
Neugen Labs +91-8133254502 +91-8133254502 Karnataka, India 195 58 Inquiry
Humble Healthcare Limited +91-9720093000 +91-8006400378 Uttar Pradesh, India 141 58 Inquiry
Sumar Biotech LLP +91-7984183709 +91-9824575381 Gujarat, India 22 58 Inquiry
Aspen Biopharma Labs Pvt Ltd +91-9248058660 +91-9248058662 Telangana, India 234 58 Inquiry
Manus Aktteva +91 (79) 6512-3395 New Delhi, India 581 34 Inquiry
HETERO LABS LTD (630) 931-6800 New Delhi, India 97 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
CHEMSWORTH +91-261-2397244 New Delhi, India 6707 30 Inquiry
A.J Chemicals 91-9810153283 New Delhi, India 6124 58 Inquiry
Supplier Advantage
Salvavidas Pharmaceutical Pvt., Ltd. 58
Neugen Labs 58
Humble Healthcare Limited 58
Sumar Biotech LLP 58
Aspen Biopharma Labs Pvt Ltd 58
Manus Aktteva 34
HETERO LABS LTD 58
CLEARSYNTH LABS LTD. 58
CHEMSWORTH 30
A.J Chemicals 58

388082-78-8(Lapatinib ditosylate)Related Search:

Lapatinib PENTA(ETHYLENE GLYCOL) DI-P-TOLUENESULFONATE Pazopanib Osimertinib mesylate Baricitinib
Afatinib 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide hydrate Cabazitaxel Pazopanib Hydrochloride Regorafenib
Afatinib dimaleate AZD-9291 Nintedanib Ethanesulfonate Salt 2-mercapto-N-methylbenzamide N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine
5-[4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl]-2-furaldehyde 2-Aminoethylmethylsulfone hydrochloride p-Toluenesulfonic acid
chevron_left

1of4

chevron_right
Lapatinib ditosylate benzenesulfonic acid: N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6 -[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine: h ydrate N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate) Lapatinib Ditosilate Lapatinib, Tykerb, GW572016 Lapatinib Ditosylate (GW-572016) lapatinib(GW572016) bis(N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(Methylsulfonyl)ethylaMino)Methyl)furan-2-yl)quinazolin-4-aMine) tetrakis(4-Methylbenzenesulfonate) hydrate Lapatinb 4-QuinazolinaMine, N-[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]-6-[5-[[[2-(Methylsulfonyl)ethyl]aMino]Methyl]-2-furanyl]-, bis(4-Methylbenzenesulfonate), Monohydrate (9CI) N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate) monohydrate 4-QuinazolinaMine, N-[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]-6-[5-[[[2-(Methylsulfonyl)ethyl]aMino]Methyl]-2-furanyl]-, bis(4-Methylbenzenesulfonate), Monohydrate xyene sulfonate lapatinib (N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(Methylsulfonyl)ethylaMino)Methyl)furan-2-yl)quinazolin-4-aMine)bis(4-Methylbenzenesulfonate) hydrate Lapatinib ditosylate N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate) N-(3-Chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)-quinazolin-4-ylamine ditosylate hydrate Rapatinib bis - toluene sulfonate GW-572016;GW572016 Lapatinib xylene sulfonate N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine, 4-methylbenzenesulfonate, hydrate (1:2:1) Lapatinib Ditosylate MonohydrateI Lapatinib ditosylate hydrat Lapatinib ditoluenesulfonate monohydrate Lapatinib tosilate hydrate Lapatinib ditosylate ISO 9001：2015 REACH Lapatinib D4 DitosylateQ: What is Lapatinib D4 Ditosylate Q: What is the CAS Number of Lapatinib D4 Ditosylate Lapatinib tosilate Lapatinib ditosylate Monohydrate Lapatinib ditosylate hydrate Lapatinib p-toluenesulfonate monohydrate GW2016 ditosylate (E)-Ferulic acid-d Lapatinib ditosylate monohydrate|||Lapatinib ditoluenesulfonate monohydrate|||Lapatinib tosilate hydrate|||Lapatinib tosilate|||Tykerb|||Tyverb 388082-78-8 388083-78-8 388082-78-9 C29H26ClFN4O4S2C7H8O3 C29H26ClFN4O4S2C7H8O3S C41H40ClFN4O11S3 C29H26ClFN4O4S2C74H8O3SH2O C29H26ClFN4O4S2C7H8O3SH2O C43H44ClFN4O11S3 2C7H8O3SC29H26ClFN4O4S anti-neoplastic Inhibitors Anti-cancer&immunity Lapatinib API 388082-78-8